SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with intense anticipation for its Phase 3 REGAL trial results, as the extended timeline is widely seen by the community as a positive indicator of 'curative outcomes' and a potential buyout. Investors are largely dismissing bearish sentiment and focusing on increasing institutional interest and the transformative potential of the company's dual cancer platforms.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting a significant Q4 earnings beat driven by strong MIPLYFFA sales, which is signaling a shift to profitability and sparking community discussions about its re-rating potential and a possible short squeeze.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

CHAC is trending as its merger target, Xanadu Quantum Technologies, announced a significant collaboration with AMD to accelerate quantum computing for aerospace and engineering, fueling community excitement over its real-world applications and strong client roster. Investors are actively watching the anticipated merger, with many adding the pure-play photonic quantum computing leader to their watchlists and discussing its potential compared to past successful SPACs in the burgeoning sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following its announcement of a proposed convertible senior notes offering, which has sparked community concern over potential dilution and questions regarding management's capital strategy despite significant existing cash reserves. Many are expressing frustration, especially in contrast to positive developments from its partner, Vertex Pharmaceuticals.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending following a mixed earnings report that saw an EPS beat but a revenue miss and cautious forward guidance, sparking debate among investors. Bulls are highlighting strengthened cash flow and the company's underlying real estate value, while bears point to soft sales and the challenging retail landscape, all amplified by significant short interest.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending down significantly following its reported quarterly loss and a weaker outlook, coupled with the announcement that its co-founders plan to leave to start a new mRNA company. Despite this, positive Phase 3 oncology data and a major analyst upgrade are sparking community debate, with many investors viewing the sharp decline as a buying opportunity given the company's substantial cash reserves and focused cancer pipeline.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as a recent business update indicates building commercial momentum for its gene therapy ZEVASKYN, with strong patient identification and expanding qualified treatment centers, fueling community optimism for profitability by Q2. This comes amidst multiple analyst upgrades reinforcing the belief that the stock is currently undervalued, despite some acknowledging the launch has progressed slower than initially expected.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amprius Technologies (NYSE:AMPX) Price Target Raised to $22.00 at B. Riley Financial

B. Riley Financial raised their price target on shares of Amprius Technologies from $16.00 to $22.00 and gave the company a "buy" rating in a report on Monday...

Scholastic (NASDAQ:SCHL) Stock Rating Lowered by B. Riley Financial

B. Riley Financial cut shares of Scholastic from a "buy" rating to a "neutral" rating in a research report on Monday...

B. Riley Financial Lowers Tecnoglass (NYSE:TGLS) Price Target to $65.00

B. Riley Financial reduced their target price on shares of Tecnoglass from $70.00 to $65.00 and set a "buy" rating for the company in a research note on Friday...

Traeger (NYSE:COOK) Given "Neutral" Rating at B. Riley Financial

B. Riley Financial reiterated a "neutral" rating and set a $0.80 price objective (down from $1.00) on shares of Traeger in a research report on Friday...

B. Riley Financial Cuts Stagwell (NASDAQ:STGW) Price Target to $7.00

B. Riley Financial lowered their price target on Stagwell from $9.00 to $7.00 and set a "buy" rating on the stock in a research report on Friday...

NN (NASDAQ:NNBR) Price Target Lowered to $3.00 at B. Riley Financial

B. Riley Financial reduced their price objective on shares of NN from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday...

B. Riley Financial Reaffirms Buy Rating for OptimizeRx (NASDAQ:OPRX)

B. Riley Financial reissued a "buy" rating and set a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research report on Friday...

Marvell Technology's (MRVL) Buy Rating Reiterated at B. Riley Financial

B. Riley Financial reissued a "buy" rating and issued a $135.00 price objective (up from $130.00) on shares of Marvell Technology in a research note on Friday...

B. Riley Financial Has Lowered Expectations for Horizon Technology Finance (NASDAQ:HRZN) Stock Price

B. Riley Financial dropped their price target on shares of Horizon Technology Finance from $7.00 to $5.50 and set a "neutral" rating on the stock in a research note on Friday...

Global Ship Lease (NYSE:GSL) Given New $48.00 Price Target at B. Riley Financial

B. Riley Financial upped their price target on shares of Global Ship Lease from $42.00 to $48.00 and gave the company a "buy" rating in a research note on Friday...

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

Current Price	$7.38
Prev Close	$7.48
Open	$7.25
Dividend Yield	21.79%
50-Day Moving Average	$7.29
Beta	1.59
Avg. Volume	624,352.78
PE Ratio	1.52

52-Week High	$10.97
52-Week Low	$2.67
Market Capitalization	$230.39M
EPS (Annual)	-$32.63
Price to Book	-0.87
Revenue Per Employee	$437,942.12

RILY
B. Riley Financial Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RILY News

RILYB. Riley Financial Inc